Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611509 | 0.98 | NPC1 (0.50) | NPC1RAB9APTPN1PTPN6PTPN11 | |
| Bromide SCHEMBL20547060 | 0.96 | NPC1 (0.49) | NPC1RAB9APTPN1PTPN6PTPN11 | |
| SCHEMBL12198408 | 0.95 | NPC1 (0.47) | NPC1RAB9APTPN1PTPN6PTPN11 | |
| SCHEMBL17083313 | 0.90 | MEP1B (0.53) | NPC1RAB9APTPN1PTPN6PTPN11 | |
| SCHEMBL17083309 | 0.90 | MEP1B (0.53) | NPC1RAB9APTPN1PTPN6PTPN11 | |
| SCHEMBL14215518 | 0.90 | RORC (0.55) | NPC1RAB9APTPN1PTPN6PTPN11 | |
| SCHEMBL8575850 | 0.90 | ACHE (0.52) | NPC1RAB9APTPN1PTPN6PTPN11 | |
| SCHEMBL10958880 | 0.90 | NR1D1 (0.51) | NPC1RAB9APTPN1PTPN6PTPN11 | |
| SCHEMBL2338811 | 0.89 | MEP1B (0.58) | NPC1RAB9APTPN1ALDH1A1MAPT | |
| SCHEMBL13225606 | 0.89 | PTPN1 (0.43) | NPC1RAB9APTPN1PTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106187863-A | The preparation method of penfluridol | 湖南中南制药有限责任公司 | 2016-12-07 | — | — | CN | claimed |
| US-12637422-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4527831-A2 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4310075-A2 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3558943-B1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20210323914-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-10961188-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200109113-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3558943-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119163-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | PAYNE JOSEPH E (US) | 2018-06-28 | — | — | WO | disclosed |
| CN-106187863-A | The preparation method of penfluridol | 湖南中南制药有限责任公司 | 2016-12-07 | — | — | CN | disclosed |
| US-20100124702-A1 | High Energy Composite Cathodes for Lithium Ion Batteries | PHYSICAL SCIENCES, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100124702-A1 | High Energy Composite Cathodes for Lithium Ion Batteries | PHYSICAL SCIENCES, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20070298219-A1 | Optical Information Recording Medium and Information Recording Method | FUJIFILM CORPORATION (JP) | 2007-12-27 | — | — | US | disclosed |
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1590344-A4 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1590344-A2 | ANTI-CANCER MEDICAMENTS | Deciphera Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040176395-A1 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2004-09-09 | — | — | US | disclosed |
| WO-2004060305-A2 | ANTI-CANCER MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-0292689-A2 | Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclo-dodecane and analogs | BRACCO INTERNATIONAL B.V. (NL) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109113-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | RNASEH1, RNASE1, HNRNPA1 | NPC1 30/4885RAB9A 1653/4885PTPN1 4569/4885 |
| US-10961188-B2 | Ionizable cationic lipid for RNA delivery | RNASEH1, RNASE1, HNRNPA1 | NPC1 30/4885RAB9A 1653/4885PTPN1 4569/4885 |
| US-20070298219-A1 | Optical Information Recording Medium and Information Recording Method | CACNA1S, CACNA1E, GRIN1 | NPC1 4268/4885RAB9A 2247/4885PTPN1 3960/4885 |
| US-20040176395-A1 | Anti-cancer medicaments | ABL1, ABL2, SRC | NPC1 4548/4885RAB9A 2813/4885PTPN1 479/4885 |
| US-20210323914-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | RNASEH1, RNASE1, HNRNPA1 | NPC1 30/4885RAB9A 1653/4885PTPN1 4569/4885 |
| US-12637422-B2 | Ionizable cationic lipid for RNA delivery | POLRMT, SLC27A1, SLC43A1 | NPC1 12/4885RAB9A 1821/4885PTPN1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.